
    
      A multicenter, multinational, double-masked, parallel-group, dose-ranging, active-controlled,
      randomized trial, which will randomize approximately 1140 subjects in a ratio of 1:1:1 to
      receive IVT injections of 0.5 mg conbercept, 1.0 mg conbercept, or 2.0 mg aflibercept. The
      trial includes a screening period of less than or equal to 14 days, followed by a treatment
      period of 92 weeks (last assessment at 96 weeks) with primary efficacy analysis at 36 weeks.
    
  